Adbry and Dupixent are used to treat moderate to severe atopic dermatitis in certain children. Adbry is used in children ages 12 years and older. Dupixent is used in children ages 6 months and older.

If you have atopic dermatitis, a skin condition commonly known as eczema, prescription creams or other topical medicines and moisturizers are usually enough to manage it. However, if your eczema is ...

LEO Pharma has announced long term safety and efficacy data for its atopic dermatitis treatment, Adbry (tralokinumab-ldrm), demonstrating the drug’s ability to drive clear or almost clear skin for up ...

Findings showed 21% of patients treated with tralokinumab achieved an IGA score of 0 or 1 at week 16 compared with 4% of those who received placebo. The Food and Drug Administration (FDA) has expanded ...

The Adbry autoinjector is for use in adults only. A new single-dose autoinjector presentation of Adbry ® (tralokinumab-ldrm) is now available for use in the treatment of moderate to severe atopic ...

Please provide your email address to receive an email when new articles are posted on . Full results of the long-term ECZTEND trial of Adbry for atopic dermatitis were announced at the Fall Clinical ...

Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma's rival antibody tralokinumab. IL-13 inhibitor ...

MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry ™ (tralokinumab-ldrm) for the treatment of moderate-to-severe atopic ...

Hoping to cut into the dominance of Dupixent, Leo Pharma of Denmark has gained FDA approval for Adbry (tralokinumab) as a treatment for moderate to severe atopic dermatitis. The injected antibody drug ...

Interim post-hoc efficacy analysis from ECZTEND, an open-label, 5-year extension trial, showed long-term improvements in extent and severity of atopic dermatitis and itch in a subgroup of adult ...

LEO Pharma has shared final results from a long-term extension study of its atopic dermatitis (AD) drug Adbry (tralokinumab-ldrm) in adult and adolescent patients aged 12 years and older with moderate ...

Please provide your email address to receive an email when new articles are posted on . Adbry is now available in the U.S. as a 300 mg/2 mL single-dose autoinjector for adults with atopic dermatitis.